Pyxis Oncology, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PYXS research report →
Companywww.pyxisoncology.com
Pyxis Oncology, Inc. , a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors.
- CEO
- Thomas Civik
- IPO
- 2021
- Employees
- 44
- HQ
- Boston, MA, US
Price Chart
Valuation
- Market Cap
- $123.54M
- P/E
- -1.51
- P/S
- 8.91
- P/B
- 3.96
- EV/EBITDA
- -1.68
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.81%
- Op Margin
- -619.61%
- Net Margin
- -589.80%
- ROE
- -135.60%
- ROIC
- -173.38%
Growth & Income
- Revenue
- $13.86M · -14.17%
- Net Income
- $-79,621,000 · -2.96%
- EPS
- $-1.28 · 3.03%
- Op Income
- $-84,420,000
- FCF YoY
- -9.67%
Performance & Tape
- 52W High
- $5.55
- 52W Low
- $0.97
- 50D MA
- $1.75
- 200D MA
- $2.23
- Beta
- 1.43
- Avg Volume
- 443.02K
Get TickerSpark's AI analysis on PYXS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 24, 26 | Dupont Jakob | other | 45,867 |
| Mar 24, 26 | Wadhane Jitendra | other | 109,461 |
| Mar 24, 26 | Wadhane Jitendra | other | 262,635 |
| Mar 24, 26 | FLAVIN JOHN L | other | 45,867 |
| Mar 24, 26 | Metzger Michael A | other | 45,867 |
| Mar 24, 26 | Lewis-Hall Freda C | other | 45,867 |
| Mar 24, 26 | Cline Darren S | other | 45,867 |
| Mar 24, 26 | HUMPHREY RACHEL | other | 45,867 |
| Mar 24, 26 | Palani Santhosh | other | 45,867 |
| Apr 14, 25 | HUMPHREY RACHEL | sell | 1,400 |
Our PYXS Coverage
We haven't published any research on PYXS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PYXS Report →